Restructuring and other costs in the first and second quarters of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities.

In the first and second quarters of fiscal year 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the Company’s workforce.

Restructuring and other costs in the first and second quarters of fiscal year 2025 primarily consisted of charges for workforce reductions and facility consolidations, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities.

Restructuring and other costs, which are included in the selling, general and administrative expenses in the consolidated statements of operations, by segment were as follows:


	Three Months Ended				Six Months Ended
	July 5, 2026		June 29, 2025		July 5, 2026		June 29, 2025
	(In thousands)
Life Sciences	$	5,926	$	1,917	$	9,155	$	4,445
Diagnostics	29,582		9,233		37,136		9,368
Corporate	—		53		(108)		629
	$	35,508	$	11,203	$	46,183	$	14,442

The following table summarizes the changes in the Company’s accrued restructuring balance for the six months ended July 5, 2026. Other amounts reported as restructuring and other costs during the six months ended July 5, 2026 in the accompanying condensed consolidated statement of operations have been summarized in the notes to the table. Remaining obligations related to these accounts are expected to be paid over the next 12 months and are included in accrued expenses and other current liabilities in the condensed consolidated balance sheets.


	(In thousands)








Balance at December 28, 2025	$	17,793
Net restructuring charges incurred in 2026 (a)	41,311
Payments	(26,286)

Balance at July 5, 2026	$	32,818